Subcutaneous Amivantamab Shows Noninferior ORR vs IV Formulation in EGFR+ NSCLC
Encorafenib/Binimetinib Induction Before Nivolumab/Ipilimumab Does Not Boost PFS in BRAF V600E/K+ Metastatic Melanoma
Amivantamab Plus Lazertinib Improves PFS Irrespective of Risk in EGFR-Mutant NSCLC
BrECADD Regimen Improves PFS vs eBEACOPP Regimen in Advanced Classical Hodgkin Lymphoma